LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal

Lilly is set to acquire Centessa for up to $7.8B, adding sleep-disorder drug candidates to its portfolio. The deal advances Lilly's strategy to diversify revenue and R&D beyond its obesity and diabetes franchises, lowering concentration risk and supporting medium-term growth prospects.

Analysis

Lilly is set to acquire Centessa for up to $7.8B, adding sleep-disorder drug candidates to its portfolio. The deal advances Lilly's strategy to diversify revenue and R&D beyond its obesity and diabetes franchises, lowering concentration risk and supporting medium-term growth prospects.